Daniel Schneiderman

Daniel Schneiderman

Director of Finance/CFO at PASITHEA THERAPEUTICS CORP.

Net worth: 13 147 $ as of 29/09/2026

48 year
Health Technology
Finance
Consumer Services

Profile

Daniel H.
Schneiderman
is Chief Financial Officer at Pasithea Therapeutics Corp.
since 2022.
Formerly, Mr. Schneiderman was Chief Financial Officer at GridAI Technologies Corp.
from 2020 to 2022, Secretary, Vice President-Finance & Controller at MetaStat, Inc. from 2012 to 2018, Chief Financial Officer at Biophytis SA from 2018 to 2019, Vice President-Investment Banking at Burnham Hill Partners LLC from 2004 to 2012, Director at Unleashed Ny from 1996 to 2000, and Chief Financial Officer at Biophytis, Inc. Education includes undergraduate studies at Tulane University (Louisiana).

Known holdings in public companies

CompanyDateNumber of sharesValuationValuation date
23/07/2026 26,667 ( 0.08% ) 13 147 $ 29/09/2026

Daniel Schneiderman active positions

CompaniesPositionStart
PASITHEA THERAPEUTICS CORP. Director of Finance/CFO 10/10/2022

Former positions of Daniel Schneiderman

CompaniesPositionEnd
GRIDAI TECHNOLOGIES CORP. Director of Finance/CFO 27/02/2022
BIOPHYTIS S.A. Director of Finance/CFO 30/11/2019
METASTAT, INC. Comptroller/Controller/Auditor 31/07/2018
Corporate Officer/Principal 31/12/2011
Unleashed Ny
Director/Board Member 31/12/1999
See the detail of Daniel Schneiderman's experience

Education of Daniel Schneiderman

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

Connections

38

1st degree connections

8

1st degree companies

Male

Female

Members of the board

Executives

Linked companies

Private companies8

Finance

Consumer Services

Health Technology

Producer Manufacturing

Health Technology

Unleashed Ny

Health Technology

Health Technology

  1. Stock Market
  2. Insiders
  3. Daniel Schneiderman